
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Dateline City: KENILWORTH, N.J. & MIAMI Clinical Studies of EIDD-2801 for the Treatment of Patients…

Dateline City: KENILWORTH, N.J. & MIAMI Clinical Studies of EIDD-2801 for the Treatment of Patients…

Dateline City: KENILWORTH, N.J. Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine…

Dateline City: KENILWORTH, N.J. Merck is Contributing 300,000 Masks to New Jersey’s Office of Homeland…

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–In response to the calls for personal protective equipment…